Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

Northwell Health

Status: Completed

Conditions: Pulmonary Arterial Hypertension

Treatments: Other: Blood draw

Study type: Interventional

Funder types: Other

Identifiers

NCT00566423

07-030

NS-LIJHS IRB # 07-030

Details and patient eligibility

About

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

Full description

As above

Enrollment: 75 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
• Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.

Exclusion criteria

• Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

75 participants in 1 patient group

1

Experimental group

Description:

Patients with Pulmonary Arterial Hypertension

Treatment:

Other: Blood draw